Is the EUNETHTA HTA CORE MODEL® fit for Purspose? Evaluation from an Industry Perspective

Marlene Gyldmark, Kristian Lampe, Jörg Ruof, Johannes Pöhlmann, Ansgar Hebborn, Finn Børlum Kristensen

Research output: Contribution to journalJournal articleResearchpeer-review

84 Downloads (Pure)

Abstract

Objectives:The HTA Core Model® was developed to improve the transferability of health technology assessment (HTA) between settings. The model has been used by HTA agencies but is also of interest to manufacturers, for improving internal evidence generation and communicating with other HTA stakeholders. To establish if the model is fit for purpose from an industry perspective, the pharmaceutical company Roche, collaborating with the European Network for HTA (EUnetHTA), conducted an assessment of the model.Methods:A questionnaire was developed to evaluate all assessment elements in the HTA Core Model v2.0 for their usefulness in meeting payers' evidence needs and demonstrating value. The questionnaire was completed by country affiliate teams working in evidence generation and reimbursement submissions for pharmaceuticals. Survey results were discussed in workshops to ensure consistency and alignment between teams.Results:The questionnaire was completed by six teams. An additional team from global pricing and market access participated in workshops. Model domains pertaining to the health problem and current technology use, technology description, clinical effectiveness, and economic value were considered most important because they meet payers' evidence needs. Overall, the model was considered useful to improve the efficiency of HTA evidence generation, share evidence internally, and communicate value to payers and HTA agencies.Conclusions:From an industry perspective, the HTA Core Model provides a useful framework and common terminology for efficient generation of transferable HTA evidence. The timeliness, efficiency, and transparency of HTA processes could be improved by a more standardized approach to HTA across settings.

Original languageEnglish
JournalInternational Journal of Technology Assessment in Health Care
Volume34
Issue number5
Pages (from-to)458-463
ISSN0266-4623
DOIs
Publication statusPublished - 18. Oct 2018

Fingerprint

Education
Terminology
Surveys and Questionnaires
Health
Pharmaceutical Preparations

Keywords

  • Biomedical
  • Biomedical technology
  • Economics
  • Healthcare sector
  • Pharmaceutical
  • Reference standards
  • Technology assessment
  • Models, Theoretical
  • Drug Industry
  • Surveys and Questionnaires
  • Technology Transfer
  • Technology Assessment, Biomedical

Cite this

Gyldmark, Marlene ; Lampe, Kristian ; Ruof, Jörg ; Pöhlmann, Johannes ; Hebborn, Ansgar ; Kristensen, Finn Børlum. / Is the EUNETHTA HTA CORE MODEL® fit for Purspose? Evaluation from an Industry Perspective. In: International Journal of Technology Assessment in Health Care. 2018 ; Vol. 34, No. 5. pp. 458-463.
@article{0bf5635e87de46d4878be70b61c1900f,
title = "Is the EUNETHTA HTA CORE MODEL{\circledR} fit for Purspose? Evaluation from an Industry Perspective",
abstract = "Objectives:The HTA Core Model{\circledR} was developed to improve the transferability of health technology assessment (HTA) between settings. The model has been used by HTA agencies but is also of interest to manufacturers, for improving internal evidence generation and communicating with other HTA stakeholders. To establish if the model is fit for purpose from an industry perspective, the pharmaceutical company Roche, collaborating with the European Network for HTA (EUnetHTA), conducted an assessment of the model.Methods:A questionnaire was developed to evaluate all assessment elements in the HTA Core Model v2.0 for their usefulness in meeting payers' evidence needs and demonstrating value. The questionnaire was completed by country affiliate teams working in evidence generation and reimbursement submissions for pharmaceuticals. Survey results were discussed in workshops to ensure consistency and alignment between teams.Results:The questionnaire was completed by six teams. An additional team from global pricing and market access participated in workshops. Model domains pertaining to the health problem and current technology use, technology description, clinical effectiveness, and economic value were considered most important because they meet payers' evidence needs. Overall, the model was considered useful to improve the efficiency of HTA evidence generation, share evidence internally, and communicate value to payers and HTA agencies.Conclusions:From an industry perspective, the HTA Core Model provides a useful framework and common terminology for efficient generation of transferable HTA evidence. The timeliness, efficiency, and transparency of HTA processes could be improved by a more standardized approach to HTA across settings.",
keywords = "Biomedical, Biomedical technology, Economics, Healthcare sector, Pharmaceutical, Reference standards, Technology assessment, Models, Theoretical, Drug Industry, Surveys and Questionnaires, Technology Transfer, Technology Assessment, Biomedical",
author = "Marlene Gyldmark and Kristian Lampe and J{\"o}rg Ruof and Johannes P{\"o}hlmann and Ansgar Hebborn and Kristensen, {Finn B{\o}rlum}",
year = "2018",
month = "10",
day = "18",
doi = "10.1017/S0266462318000594",
language = "English",
volume = "34",
pages = "458--463",
journal = "International Journal of Technology Assessment in Health Care",
issn = "0266-4623",
publisher = "Heinemann",
number = "5",

}

Is the EUNETHTA HTA CORE MODEL® fit for Purspose? Evaluation from an Industry Perspective. / Gyldmark, Marlene; Lampe, Kristian; Ruof, Jörg; Pöhlmann, Johannes; Hebborn, Ansgar; Kristensen, Finn Børlum.

In: International Journal of Technology Assessment in Health Care, Vol. 34, No. 5, 18.10.2018, p. 458-463.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Is the EUNETHTA HTA CORE MODEL® fit for Purspose? Evaluation from an Industry Perspective

AU - Gyldmark, Marlene

AU - Lampe, Kristian

AU - Ruof, Jörg

AU - Pöhlmann, Johannes

AU - Hebborn, Ansgar

AU - Kristensen, Finn Børlum

PY - 2018/10/18

Y1 - 2018/10/18

N2 - Objectives:The HTA Core Model® was developed to improve the transferability of health technology assessment (HTA) between settings. The model has been used by HTA agencies but is also of interest to manufacturers, for improving internal evidence generation and communicating with other HTA stakeholders. To establish if the model is fit for purpose from an industry perspective, the pharmaceutical company Roche, collaborating with the European Network for HTA (EUnetHTA), conducted an assessment of the model.Methods:A questionnaire was developed to evaluate all assessment elements in the HTA Core Model v2.0 for their usefulness in meeting payers' evidence needs and demonstrating value. The questionnaire was completed by country affiliate teams working in evidence generation and reimbursement submissions for pharmaceuticals. Survey results were discussed in workshops to ensure consistency and alignment between teams.Results:The questionnaire was completed by six teams. An additional team from global pricing and market access participated in workshops. Model domains pertaining to the health problem and current technology use, technology description, clinical effectiveness, and economic value were considered most important because they meet payers' evidence needs. Overall, the model was considered useful to improve the efficiency of HTA evidence generation, share evidence internally, and communicate value to payers and HTA agencies.Conclusions:From an industry perspective, the HTA Core Model provides a useful framework and common terminology for efficient generation of transferable HTA evidence. The timeliness, efficiency, and transparency of HTA processes could be improved by a more standardized approach to HTA across settings.

AB - Objectives:The HTA Core Model® was developed to improve the transferability of health technology assessment (HTA) between settings. The model has been used by HTA agencies but is also of interest to manufacturers, for improving internal evidence generation and communicating with other HTA stakeholders. To establish if the model is fit for purpose from an industry perspective, the pharmaceutical company Roche, collaborating with the European Network for HTA (EUnetHTA), conducted an assessment of the model.Methods:A questionnaire was developed to evaluate all assessment elements in the HTA Core Model v2.0 for their usefulness in meeting payers' evidence needs and demonstrating value. The questionnaire was completed by country affiliate teams working in evidence generation and reimbursement submissions for pharmaceuticals. Survey results were discussed in workshops to ensure consistency and alignment between teams.Results:The questionnaire was completed by six teams. An additional team from global pricing and market access participated in workshops. Model domains pertaining to the health problem and current technology use, technology description, clinical effectiveness, and economic value were considered most important because they meet payers' evidence needs. Overall, the model was considered useful to improve the efficiency of HTA evidence generation, share evidence internally, and communicate value to payers and HTA agencies.Conclusions:From an industry perspective, the HTA Core Model provides a useful framework and common terminology for efficient generation of transferable HTA evidence. The timeliness, efficiency, and transparency of HTA processes could be improved by a more standardized approach to HTA across settings.

KW - Biomedical

KW - Biomedical technology

KW - Economics

KW - Healthcare sector

KW - Pharmaceutical

KW - Reference standards

KW - Technology assessment

KW - Models, Theoretical

KW - Drug Industry

KW - Surveys and Questionnaires

KW - Technology Transfer

KW - Technology Assessment, Biomedical

U2 - 10.1017/S0266462318000594

DO - 10.1017/S0266462318000594

M3 - Journal article

VL - 34

SP - 458

EP - 463

JO - International Journal of Technology Assessment in Health Care

JF - International Journal of Technology Assessment in Health Care

SN - 0266-4623

IS - 5

ER -